Systemic Anti-Cancer Therapy Regimen Library
GYN OV Advanced - niraparib
Treatment Overview
Recommended starting dose of niraparib for first-line maintenance treatment of advanced ovarian cancer is dependent on the patients weight and platelet count:
- For body-weight less than 77 kg or baseline platelet count less than 150 x 109/L the recommended starting dose of niraparib is 200 mg ONCE daily;
- For body-weight 77 kg or greater and baseline platelet count 150 x 109/L or greater the recommended starting dose of niraparib is 300 mg ONCE daily.
Use the regimen below specific for the patient.
Recommended starting dose for body-weight less than 77 kg or baseline platelet count less than 150 x 109/L.
Recommended starting dose for body-weight 77 kg or greater and baseline platelet count 150 x 109/L or greater.
Supportive Care Factors
| Factor | Value |
|---|---|
| Emetogenicity: | Medium to high |
References
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.